EP1663149A2 - Bibn 4096 amorphe seche par pulverisation, procede de production dudit compose ainsi que son utilisation en tant que substance a inhaler - Google Patents

Bibn 4096 amorphe seche par pulverisation, procede de production dudit compose ainsi que son utilisation en tant que substance a inhaler

Info

Publication number
EP1663149A2
EP1663149A2 EP04764016A EP04764016A EP1663149A2 EP 1663149 A2 EP1663149 A2 EP 1663149A2 EP 04764016 A EP04764016 A EP 04764016A EP 04764016 A EP04764016 A EP 04764016A EP 1663149 A2 EP1663149 A2 EP 1663149A2
Authority
EP
European Patent Office
Prior art keywords
active ingredient
weight
drying gas
particularly preferably
spray
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04764016A
Other languages
German (de)
English (en)
Inventor
Michael Trunk
Claudius Weiler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim International GmbH
Publication of EP1663149A2 publication Critical patent/EP1663149A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine

Definitions

  • the invention relates to the CGRP antagonist 1 - [/ V 2 - [3,5-dibromo- ⁇ / - [[4- (3,4-dihydro-2 (1H) -oxoquinazolin-3-yl) -1-piperidinyl ] carbonyl] -D-tyrosyl] -L-lysyl] -4- (4-pyridinyl) - piperazine (A) and its physiologically tolerable salts, which in the amorphous state under normal conditions (T ⁇ 50 ° C, relative humidity ⁇ 75% ) are stable and in the form of microparticles, processes for the production of such microparticles from these substances and the use of these particles for the production of a medicament of the application form powder inhalant for pulmonary and nasal inhalation, in particular for the production of a medicament for the treatment of headaches, migraines and cluster headache.
  • the CGRP antagonist 1- [ ⁇ / 2 - [3,5-dibromo- ⁇ / - [[4- (3,4-dihydro-2 (1H) -oxoquinazolin-3-yl) -1-piperidinyl ] carbonyl] -D-tyrosyl] -L-lysyl] -4- (4-pyridinyl) -piperazine (A) is known from international patent application PCT / EP97 / 04862 (published as WO 98/11128) and has the following structure on:
  • the active ingredient base (A) is a highly effective CGRP antagonist for the acute and prophylactic treatment of headaches, especially migraines and cluster headache, the application of which is not possible by oral route using classic dosage forms, since the substance has only a low oral bioavailability.
  • an active ingredient to be available systemically as quickly as possible. It should be noted that the application is straightforward for the patient and no other conditions that can influence the bioavailability (eg "food effect") lead to a restriction of the applicability for the patient.
  • Active ingredients that are to be available systemically are usually made available by oral administration. If this route cannot be implemented or is desired due to special properties of the active ingredient or special requirements for the application, various other options for the systemic administration of substances are known in the prior art.
  • the inhalation route has been discussed for some time, by means of which active ingredients can also be made systemically available in addition to topical applications.
  • Powder inhalation lends itself to substances that are critical due to their decomposition behavior in solution or have poor solubility per se.
  • the absolute amount of the active ingredient that has to be administered in one application represents a particular challenge for the formulation.
  • the physical stability eg aerodynamic particle size, dispersibility, physicochemical properties
  • the active ingredient also proves to be a critical challenge for development and manufacture a powder inhalant.
  • inhalation powders which are filled, for example, into suitable capsules (inhalettes), are applied to the lungs by means of powder inhalers. Also known are other systems in which the amount of powder to be applied is pre-metered (eg blister), as well as multidose powder systems.
  • inhalative use can also be carried out by applying suitable powdered inhalation aerosols which are suspended, for example, in HFA134a, HFA227 or their mixture as propellant.
  • suitable powdered inhalation aerosols which are suspended, for example, in HFA134a, HFA227 or their mixture as propellant.
  • the microparticles of a pure active ingredient are applied through the respiratory tract on the surface of the lungs, for example in the alveoli, by means of the inhalation process.
  • Inhalation systems are known in the literature in which the active ingredient is present in the form of solid particles either as a micronized suspension in a suitable solvent system as a carrier or in the form of a dry powder.
  • Powder inhalants for example in the form of capsules for inhalation, are usually produced on the basis of the general teaching as described in DE-A-179 22 07. A critical factor in such multi-component systems is an even distribution of the drug in the powder mixture.
  • the active pharmaceutical ingredient used to manufacture the above-mentioned medicinal products should be as pure as possible and its stability during long-term storage must be guaranteed under various environmental conditions. This is imperative in order to prevent pharmaceutical compositions from being used which, in addition to the actual active ingredient, contain, for example, degradation products thereof.
  • any change in the solid state of a drug or the active ingredient used which improves its physical and chemical stability, results in a considerable advantage over less stable forms of the same drug.
  • Different physical / physicochemical properties may, however, also bring about improved pharmacological / pharmacokinetic properties of the drug.
  • special morphological properties of solid particles can be advantageous for the production of a medicament.
  • the complex object of the present invention was therefore primarily to provide novel, stable microparticles of the active ingredient base l-IISp-ß. ⁇ - dibromo- ⁇ / - [[4- (3,4-dihydro-2 (1H) -oxoquinazoline- 3-yl) -1-piperidinyl] carbonyl] -D-tyrosyl] -L-lysyl] -4- (4-pyridinyl) -piperazine (A) and its physiologically tolerable salts which meet the above-mentioned high requirements for a Active pharmaceutical ingredients for a powder inhalative for pulmonary and nasal inhalation are sufficient and, compared to the conventional micronized starting material (obtainable, for example, by means of air jet grinding), have proven to be suitable in their use as powder inhalants with regard to their pharmacological / pharmacokinetic properties.
  • the morphology of the microparticles was to be optimized in such a way that the formulation consisting of them
  • the formulation according to the invention should furthermore show a rapid onset of action for the treatment of the acute pain states which occur very suddenly in the case of migraines. This means that a rapid absorption of the active ingredient and a rapid rise in the plasma level must be guaranteed.
  • the present invention therefore consists in providing novel, stable microparticles of the CGRP antagonist 1- [[/ 2 - [3,5-dibromo- ⁇ / - [[4- (3,4-dihydro-2 (1H) - oxoquinazoline -3-yl) -1-piperidinyl] carbonyl] -D-tyrosyl] -L-lysyl] -4- (4-pyridinyl) -piperazine (A) and its physiologically tolerable salts, which are surprisingly special for the preparation of powder inhalants are suitable for pulmonary and nasal inhalation.
  • the invention likewise encompasses the basic procedure for the production of such microparticles and their use for the production of medicaments in the dosage form of a powder inhalant.
  • the corresponding physiologically compatible acid addition salts are used, which are selected, for example, from the group consisting of 1- [ ⁇ / 2 - [3,5-dibromo- ⁇ / - [[4- (3,4-dihydro- 2 (1 / - /) - oxochir ⁇ azolin-3-yl) -1-piperidinyl] carbonyl] -D-tyrosyl] -L-lysyl] -4- (4-pyridinyl) -piperazine hydrochloride, sulfate, phosphate, Hydrobromide, carbonate, methanesulfonate, p-toluenesulfonate, nitrate, citrate, malate, tatrat, lactate, succinate, gluconate, acetate, formate, propionate, capronate, oxalate, -Maleate, -Fuma
  • Particle geometries of the microparticles which can be described as collapsed hollow spheres and have a wrinkle-like structure, were found to be advantageous.
  • particles that are produced by the processes described below have particle shapes which, depending on the test conditions, are described between the extremes “spherical shell fragment”, “thin-walled, completely collapsed sphere”, “fold-like, filigree-flaky plate structure”, and “rosette-like fold structure” can.
  • the parameter X 50 is in the range from 0.5 ⁇ m to 10 ⁇ m, preferably from 0.5 ⁇ m to 6 ⁇ m.
  • the wrinkle-like microparticles according to the invention are suitable for the production of powder inhalants for pulmonary and nasal inhalation, with no further auxiliaries or additives (carrier materials) being required in order to obtain a technically manageable powder which can be further processed directly and which has excellent properties with regard to dispersibility and is sufficiently easy to process with regard to its cohesive properties.
  • a first object of the present invention is thus a powder inhalative for pulmonary and nasal inhalation, comprising the CGRP antagonist 1- [ ⁇ / 2 - [3,5-dibromo- ⁇ / - [[4- (3,4-dihydro-2 (1H) -oxoquinazolin-3-yl) -1-piperidinyl] carbonyl] -D-tyrosyl] -L-lysyl] -4- (4-pyridinyl) -piperazine (A) or one of its physiologically compatible salts in the form of wrinkle-like microparticles, characterized in that
  • the parameter X 50 is in the range from 0.5 ⁇ m to 10 ⁇ m, preferably from 0.5 ⁇ m to 6 ⁇ m.
  • the wrinkle-like microparticles according to the invention are also suitable for producing powder inhalants in which the active ingredient is applied together with an auxiliary.
  • normal carrier materials or flow aids can be used as physiologically harmless, homogeneous auxiliaries.
  • the normal carrier materials can be selected from the group consisting of monosaccharides (e.g. glucose or arabinose), disaccharides (e.g. lactose, sucrose, maltose, trehalose), oligo- and polysaccharides (e.g. dextrans, starch, cellulose derivatives), polyalcohols (e.g. mannitol, Sorbitol, xylitol), salts (eg sodium chloride, calcium carbonate), polylactides, polyglycolides and mixtures of these auxiliaries.
  • monosaccharides e.g. glucose or arabinose
  • disaccharides e.g. lactose, sucrose, maltose, trehalose
  • oligo- and polysaccharides e.g. dextrans, starch, cellulose derivatives
  • polyalcohols e.g.
  • the flow aids can be selected, for example, from a group consisting of magnesium stearate, calcium stearate, stearic acid, stearyl alcohols, calcium behenate, calcium arachinate, hydrogenated vegetable oils such as, for example, hydrogenated castor oil or hydrogenated cottonseed oil, fatty acid esters, sodium stearyl fumurate, sodium dodecylsulfate sulfate, magnesium dodecyl sulfate, magnesium dodecyl sulfate, magnesium dodecyl sulfate, magnesium dodecyl sulfate, magnesium dodecyl sulfate and magnesium dodecyl sulfate.
  • a second object of the present invention thus comprises a production process for the microparticles of the active ingredient base (A) according to the invention, comprising the following steps:
  • microparticles of the active ingredient base (A) according to the invention are preferably produced by a process which comprises the following steps:
  • an inlet temperature of the drying gas from 100 ° C. to 350 ° C., preferably from 120 ° C. and 250 ° C. and particularly preferably from 130 ° C. to 200 ° C.,
  • a third subject of the present invention comprises a production process of the microparticles of the salts of the active substance base (A) according to the invention, comprising the following steps:
  • an inlet temperature of the drying gas from 100 ° C to 350 ° C, preferably from 120 ° C to 250 ° C and particularly preferably from 130 ° C to 200 ° C and
  • microparticles of the salts of the active ingredient base (A) according to the invention are preferably produced by a process which comprises the following steps:
  • an inlet temperature of the drying gas from 100 ° C. to 350 ° C., preferably from 120 ° C. to 250 ° C. and particularly preferably from 130 ° C. to 200 ° C.,
  • Water or an aqueous buffer system with a pH between 6 and 8 have been found to be suitable solvents for producing a sprayable solution of the salt forms of the active ingredient base (A).
  • the active ingredient in the form of the free base is brought into solution in the form of the corresponding salt in an aqueous solution, to which 0.9 to 1.1 equivalents of an acid are added, depending on the amount of active ingredient to be dissolved.
  • preferred acids are inorganic acids (for example hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid, carbonic acid), fruit acids (for example citric acid, malic acid, tartaric acid, lactic acid, succinic acid, gluconic acid), carboxylic acids (For example formic acid, acetic acid, propionic acid, hexanoic acid) and other organic acids such as oxalic acid, methanesulfonic acid, p-toluenesulfonic acid, fumaric acid, mandelic acid or maleic acid, the use of hydrochloric acid, hydrobromic acid or sulfuric acid and in particular the use of hydrochloric acid being of particular importance.
  • inorganic acids for example hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid, carbonic acid
  • fruit acids for example citric acid, malic acid, tartaric acid, lactic acid, succinic acid, gluconic
  • the surface properties of the particles can be optimized by a certain ratio between drop size and solid concentration.
  • the drop size is a crucial parameter for the generation of inhalable particles.
  • the spray gas throughput in combination with the solution throughput must be selected so that the desired drop size is achieved. Since there are a large number of parameter combinations of nozzle-spray gas throughput-solution throughput, which lead to a suitable drop size, a meaningful specification of the method about the drop size is made, which are determined with the same nozzle parameters with water at room temperature. This can be obtained by the characteristic value X o 5 (median droplet size, below which 50% of the volume-based drop portion) will be described, which should be in the range from 1 .mu.m to 50 .mu.m are.
  • the decisive parameters that flow into the drying step are the inlet and outlet temperatures of the drying gas, as well as the volume flow of the dry gas that is passed through.
  • a fourth object of the present invention relates to the use of the wrinkle-like microparticles produced by the methods described above for the manufacture of a powder inhalant.
  • a fifth object of the present invention comprises the microparticles according to the invention, obtainable according to the methods described above.
  • Measurement method To determine the particle size, the powder is fed to a laser diffraction spectrometer using a dispersing unit.
  • the median value X 50 means the particle size below which 50% of the particle quantity lies.
  • the Q (. 5 8) - value describes the percentage of the particles having a size of 5.8 microns below.
  • Measuring device Laser diffraction spectrometer (HELOS) .Fa.
  • Sympatec software WINDOX 4 dispersing unit: RODOS / dispersing pressure: 3 bar focal length: 100 mm [measuring range: 0.9 175 ⁇ m] evaluation mode: HRLD (V 4)
  • the specific surface is determined by exposing the powder sample to a nitrogen atmosphere at different pressures. By cooling the sample, the nitrogen molecules condense on the surface of the particles. The amount of condensed nitrogen is determined via the pressure drop in the system and the specific surface area of the sample is calculated using the area required by nitrogen and the sample weight.
  • Empty volume Dewar flask lowering, t: 0.5 h holding time: 20 seconds
  • Measuring device Laser diffraction spectrometer (HELOS), Sympatec Software: WINDOX 4 focal length: 100 mm [measuring range: 0.9 175 ⁇ m]
  • Measuring method The drop size is determined by removing the nozzle from the spray dryer and the spray in the upper one Third of the spray cone is placed centrally in the laser beam. The measurement is carried out at room temperature with water as the reference medium under otherwise identical conditions. 2) Example of spray parameters
  • Figures 1 and 2 show the recordings of microparticles of the active ingredient base (A), which were prepared by the process according to the invention from an alcoholic spray solution.

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne l'antagoniste de CGRP 1[N<2>-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-pipéridinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-pipérazine (A) ou des sels physiologiquement acceptables dudit composé, qui sont stables à l'état amorphe dans des conditions normales (T < 50 DEG C, humidité relative < 75%) et se présentent sous forme de microparticules. La présente invention concerne également des procédés de production de microparticules à partir de ces composés ainsi que l'utilisation de ces particules pour la fabrication d'un médicament destiné à être administré sous forme de poudre à inhaler pour l'inhalation pulmonaire et nasale, en particulier pour la fabrication d'un médicament destiné à traiter les céphalées, la migraine et l'algie vasculaire de la face.
EP04764016A 2003-08-18 2004-08-12 Bibn 4096 amorphe seche par pulverisation, procede de production dudit compose ainsi que son utilisation en tant que substance a inhaler Withdrawn EP1663149A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2003138402 DE10338402A1 (de) 2003-08-18 2003-08-18 Sprühgetrocknetes, amorphes BIBN 4096, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
PCT/EP2004/009012 WO2005018603A2 (fr) 2003-08-18 2004-08-12 Bibn 4096 amorphe seche par pulverisation, procede de production dudit compose ainsi que son utilisation en tant que substance a inhaler

Publications (1)

Publication Number Publication Date
EP1663149A2 true EP1663149A2 (fr) 2006-06-07

Family

ID=34201781

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04764016A Withdrawn EP1663149A2 (fr) 2003-08-18 2004-08-12 Bibn 4096 amorphe seche par pulverisation, procede de production dudit compose ainsi que son utilisation en tant que substance a inhaler

Country Status (5)

Country Link
EP (1) EP1663149A2 (fr)
JP (1) JP2007502789A (fr)
CA (1) CA2536047A1 (fr)
DE (1) DE10338402A1 (fr)
WO (1) WO2005018603A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
DE60318938T2 (de) 2002-03-20 2009-01-22 Mannkind Corp., Valencia Inhalationsgerät
DE10338407A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Inhalationspulver enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin
DE10338399A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mikropartikel, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-Iysyl]-4-(4-pyridinyl)-piperazin, Verfahren zu deren Herstellung sowie deren Verwendung als Inhalaltionspulver
BRPI0514263B8 (pt) 2004-08-20 2021-05-25 Mannkind Corp método para a síntese de bis-3,6-[4-aminobutil]-2,5-dicetopiperazina n-protegida
DK1791542T3 (en) 2004-08-23 2015-06-15 Mannkind Corp Diketopiperazinsalte for pharmaceutical delivery
CN104324362B (zh) 2005-09-14 2018-04-24 曼金德公司 以提高活性试剂对结晶微粒表面的亲和力为基础的药物配制方法
JP5599975B2 (ja) 2006-02-22 2014-10-01 マンカインド コーポレイション ジケトピペラジン及び活性薬剤を含有する微粒子の製剤特性の改善方法
WO2011163272A1 (fr) 2010-06-21 2011-12-29 Mannkind Corporation Système et procédé d'administration de médicament sous la forme d'une poudre sèche
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
CA3086027C (fr) 2008-06-13 2022-05-17 Mannkind Corporation Inhalateur de poudre seche et systeme d'administration de medicament
WO2009155581A1 (fr) 2008-06-20 2009-12-23 Mannkind Corporation Appareil interactif pour l’établissement en temps réel d’un profil des efforts d’inhalation
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
JP5667095B2 (ja) 2009-03-11 2015-02-12 マンカインド コーポレイション 吸入器の抵抗を測定するための装置、システムおよび方法
KR20200028501A (ko) * 2009-06-12 2020-03-16 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
CA2778698A1 (fr) 2009-11-03 2011-05-12 Mannkind Corporation Appareil et methode de simulation d'efforts d'inhalation
CA3078334C (fr) 2011-04-01 2022-08-09 Mannkind Corporation Emballage coque pour cartouches pharmaceutiques
WO2012174472A1 (fr) 2011-06-17 2012-12-20 Mannkind Corporation Microparticules de dicétopipérazine de capacité élevée
JP6018640B2 (ja) 2011-10-24 2016-11-02 マンカインド コーポレイション 疼痛を緩和するのに有効な鎮痛組成物並びに当該組成物を含む乾燥粉末及び乾燥粉末薬剤輸送システム
US9763965B2 (en) 2012-04-13 2017-09-19 Glaxosmithkline Intellectual Property Development Limited Aggregate particles
ES2624294T3 (es) 2012-07-12 2017-07-13 Mannkind Corporation Sistemas de suministro de fármacos en polvo seco
WO2014066856A1 (fr) 2012-10-26 2014-05-01 Mannkind Corporation Compositions et procédés de vaccin antigrippal inhalable
JP6523247B2 (ja) 2013-03-15 2019-05-29 マンカインド コーポレイション 微結晶性ジケトピペラジン粒子の製造方法および乾燥粉末組成物の製造方法
CA2916143C (fr) * 2013-06-19 2019-01-29 Aicuris Anti-Infective Cures Gmbh Letermovir amorphe et formulations pharmaceutiques solides destinees a etre administrees par voie orale le comprenant
MX394255B (es) 2013-07-18 2025-03-24 Mannkind Corp Composiciones farmaceuticas en polvo seco estables al calor y metodos
WO2015021064A1 (fr) 2013-08-05 2015-02-12 Mannkind Corporation Appareil d'insufflation et procédés
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1242211A (en) * 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
AU2001230533A1 (en) * 2000-02-04 2001-08-14 Kissei Pharmaceutical Co. Ltd. Powdered preparation for inhalation and powder inhalant containing the same packed
GB0014851D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
DE10139410A1 (de) * 2001-08-17 2003-02-27 Boehringer Ingelheim Pharma Verwendung von BIBN4096 in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
DE10206770A1 (de) * 2002-02-19 2003-08-28 Boehringer Ingelheim Pharma Verfahren zur Herstellung eines Pulverinhalativums enthaltend ein Salz des CGRP-Antagonisten BIBN4096
DE10207026A1 (de) * 2002-02-20 2003-08-28 Boehringer Ingelheim Kg Pulverinhalativum, enthaltend den CGRP-Antagonisten BIBN4096 und Verfahren zu dessen Herstellung
DE10338399A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mikropartikel, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-Iysyl]-4-(4-pyridinyl)-piperazin, Verfahren zu deren Herstellung sowie deren Verwendung als Inhalaltionspulver
DE10338407A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Inhalationspulver enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin
DE10338403A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierung, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyrindinyl)-piperazin, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005018603A3 *

Also Published As

Publication number Publication date
WO2005018603A2 (fr) 2005-03-03
DE10338402A1 (de) 2005-03-17
CA2536047A1 (fr) 2005-03-03
JP2007502789A (ja) 2007-02-15
WO2005018603A3 (fr) 2005-07-21

Similar Documents

Publication Publication Date Title
EP1663149A2 (fr) Bibn 4096 amorphe seche par pulverisation, procede de production dudit compose ainsi que son utilisation en tant que substance a inhaler
EP1478382B1 (fr) Procede de production d&#39;un inhalant en poudre contenant un sel de l&#39;antagoniste du cgrp bibn4096
EP1131059B1 (fr) Poudre seche pour inhalation
US20050043247A1 (en) Spray-dried amorphous BIBN 4096, process for preparing and the use thereof as inhalative
JP2007502789A6 (ja) 噴霧乾燥された無定形ｂｉｂｎ４０９６、その調製方法及び吸入剤としてのその使用
DE10126924A1 (de) Inhalationskapseln
WO2012160088A1 (fr) Nanoparticules et microparticules biocompatibles enrobées de stabilisateurs pour une application pulmonaire
DE102009015702A1 (de) Tabletten enthaltend Dapoxetin und Trockenverarbeitungsverfahren zu deren Herstellung
DE69817774T2 (de) Trägerstoff für trockenpulverinhalator, verfahren zu dessen herstellung und diesen enthaltende arzneimittel
WO2012160085A1 (fr) Particules nanopolymériques biocompatibles contenant des principes actifs pour une application pulmonaire
DE202010017303U1 (de) Trockenverarbeitung von Retigabin
DE69122780T2 (de) Benzenedimethanolderivat geeignet für mikronisierung
EP1478338B1 (fr) Poudre d&#39;inhalation contenant l&#39;antagoniste bibn4096 de cgrp et procede de fabrication
WO2005018609A1 (fr) Microparticules contenant l&#39;antagoniste de cgrp 1-[n2-[3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazine, procede de production desdites particules ainsi que leur utilisation en tant que poudre d&#39;inhalation
WO2005018614A1 (fr) Composition pulverulente contenant l&#39;antagoniste cgrp 1-[n2-(3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazine
EP1663150A2 (fr) Nouvelle poudre pour inhaler contenant l&#39;antagoniste de cgrp 1-[n2-[3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazine
JP2007502790A6 (ja) Ｃｇｒｐアンタゴニスト１−〔ｎ２−〔３，５−ジブロモ−ｎ−〔〔４−（３，４−ジヒドロ−２（１ｈ）−オキソキナゾリン−３−イル）−１−ピペリジニル〕カルボニル〕−ｄ−チロシル〕−ｌ−リシル〕−４−（４−ピリジニル）−ピペラジンを含む微粒子、その調製方法及び吸入粉末としてのその使用
EP2244696B1 (fr) Support sous forme de pastilles, leurs procédés de production et leur utilisation
WO2019048424A1 (fr) Invention concernant des nanparticules contenant des taxanes destinées à une application par inhalation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060320

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20090216

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090303